Современные Т-клеточные технологии иммунотерапии солидных опухолей

Согласно принятой концепции иммуноредактирования, взаимодействие клеток злокачественной опухоли и иммунитета представляет собой сложный многофакторный процесс, результатом которого может быть как противоопухолевая эффекторная активность, так и развитие супрессорных механизмов, способствующих опухолевому росту. Накопление научных сведений в области изучения процессов противоопухолевого иммунного ответа и толерантности привело к появлению множества исследовательских и терапевтических подходов, использующих разные звенья иммунной системы для борьбы с неопластическими процессами. Особняком среди имеющихся подходов стоят стратегии, использующие потенциал основных эффекторов адаптивного иммунитета – антигенспецифичных Т-лимфоцитов – для борьбы со злокачественными новообразованиями, появившиеся более века назад и легшие в основу исследований в области иммунотерапии рака. Одним из свидетельств значительного потенциала противоопухолевой активности Т-клеток при использовании в иммунотерапевтических схемах лечения онкологических заболеваний стал успех в терапии гематологических онкологических заболеваний, достичь которого удалось в конце минувшего десятилетия. При этом, однако, терапия солидных злокачественных новообразований по сей день сталкивается с существенными сложностями, ограничивающими эффективность лечения. В этой связи основной задачей обзора является аккумулирование актуальных сведений относительно успехов и ограничений Т-клеточной иммунотерапии в отношении солидных опухолей.

На сегодняшний день фенотип и функционал Т-клеток исследуется и модулируется как в отношении усиления противоопухолевой цитотоксичности, повышения жизнеспособности и пролиферативной активности Т-клеток, так и в отношении преодоления супрессорного влияния опухоли и ее толерогенного окружения на Т-клетки, а также обеспечения направленной миграции эффекторных Т-лимфоцитов в ткани солидных опухолей. В настоящем обзоре рассматриваются иммунотерапевтические подходы, использующие потенциал эффекторных Т-лимфоцитов, существующие на сегодняшний день в виде клинических исследований или применяемых терапевтических схем лечения солидных злокачественных новообразований. Обсуждаются антиген-независимые подходы, направленные на неспецифическое усиление Т-клеточного ответа, такие как терапия рекомбинантными цитоки нами и ингибирование checkpoint-молекул, а также антиген-зависимые, или антиген-специфичные, подходы, такие как адоптивная Т-клеточная терапия эндогенными Т-лимфоцитами или Т-клетками с модифицированным антиген-распознающим рецептором (CAR-T-клетки, TCR-T-клетки), а также использование биспецифических антител в качестве Т-клеточных активаторов. В обзоре описаны преимущества и недостатки каждого из подходов в монотерапии и существующие на сегодняшний день результаты и перспективы их комбинирования друг с другом.

1. Лежнин Ю.Н., Христиченко А.Ю., Ратникова Н.М., Кравченко Ю.Е., Чумаков С.П. Клеточная иммунотерапия – современный подход к лечению онкологических заболеваний // Медицинская иммунология, 2018. Т. 20, № 3. С. 313-340. doi: 10.15789/1563- 0625-2018-3-313-340.

2. Седых С.Е., Невинский Г.А. Способы получения и перспективы применения биспецифичных антител для лечения онкологических заболеваний // Успехи молекулярной онкологии, 2018. Т.5, № 4. С. 30-40.

3. Стенина М.Б., Царева Е.В., Жаров А.А., Тюляндин С.А. Инфильтрирующие опухоль лимфоциты: биологическая суть и клиническое значение при раке молочной железы // Российский онкологический журнал, 2016. Т. 21, № 1-2. С. 92-100.

4. Шаповал А.И., Шаповал С.П., Щербакова Н.С., Щербаков Д.Н. Молекулы контроля иммунитета семейства В7. Часть 1. Общая характеристика и первые представители: B7-1, B7-2, B7-H1, B7-H2 и B7-DC // Биоорганическая химия, 2019. Т. 45, № 4. С. 348-364.

5. Шубникова Е.В., Букатина Т.М., Вельц Н.Ю., Каперко Д.А., Кутехова Г.В. Ингибиторы контрольных точек иммунного ответа: новые риски нового класса противоопухолевых средств // Безопасность и риск фармакотерапии, 2020. Т. 8. № 1. С. 9-22.

6. Akahori Y., Wang L., Yoneyama M., Seo N., Okumura S., Miyahara Y., Amaishi Y., Okamoto S., Mineno J., Ikeda H., Maki T., Fujiwara H., Akatsuka Y., Kato T., Shiku H. Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination. Blood, 2018, Vol. 132, no. 11, pp. 1134-1145.

7. Badalamenti G., Fanale D., Incorvaia L., Barraco N., Listì A., Maragliano R., Vincenzi B., Calò V., Iovanna J.L., Bazan V., Russo A. Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? Cell Immunol., 2019, Vol. 343, 103753. doi: 10.1016/j.cellimm.2018.01.013.

8. Bargou R., Leo E., Zugmaier G., Klinger M., Goebeler M., Knop S., Noppeney R., Viardot A., Hess G., Schuler M., Einsele H., Brandl C., Wolf A., Kirchinger P., Klappers P., Schmidt M., Riethmüller G., Reinhardt C., Baeuerle P.A., Kufer P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science, 2008, Vol. 321, no. 5891, pp. 974-977.

9. Barroso-Sousa R., Ott P.A. Transformation of old concepts for a new era of cancer immunotherapy: cytokine therapy and cancer vaccines as combination partners of PD1/PD-L1 Inhibitors. Curr. Oncol. Rep., 2018, Vol. 21, no. 1, 1. doi: 10.1007/s11912-018-0738-2.

10. Beavis P.A., Henderson M.A., Giuffrida L., Mills J.K., Sek K., Cross R.S., Davenport A.J., John L.B., Mardiana S., Slaney C.Y., Johnstone R.W., Trapani J.A., Stagg J., Loi S., Kats L., Gyorki D., Kershaw M.H., Darcy P.K. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J. Clin. Invest., 2017, Vol. 127, no. 3, pp. 929-941.

11. Bedognetti D., Spivey T.L., Zhao Y., Uccellini L., Tomei S., Dudley M.E., Ascierto M.L., de Giorgi V., Liu Q., Delogu L.G., Sommariva M., Sertoli M.R., Simon R., Wang E., Rosenberg S.A., Marincola F.M. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br. J. Cancer, 2013, Vol. 109, no. 9, pp. 2412-2423.

12. Bernhard H., Neudorfer J., Gebhard K., Conrad H., Hermann C., Nährig J., Fend F., Weber W., Busch D.H., Peschel C. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2- overexpressing breast cancer. Cancer Immunol. Immunother., 2008, Vol. 57, no. 2, pp. 271-280.

13. Borgers J.S.W., Haanen J.B.A.G. Cellular therapy and cytokine treatments for melanoma. Hematol. Oncol. Clin. North Am., 2021, Vol. 35, no. 1, pp. 129-144.

14. Boyman O., Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol., 2012, Vol. 12, no. 3, pp. 180-190.

15. Bruchard M., Ghiringhelli F. Deciphering the roles of innate lymphoid cells in cancer. Front. Immunol., 2019, Vol. 10, 656. doi: 10.3389/fimmu.2019.00656.

16. Chames P., Baty D. Antibody engineering and its applications in tumor targeting and intracellular immunization. FEMS Microbiol. Lett., 2000, Vol. 189, no. 1, pp. 1-8.

17. Chandran S.S., Klebanoff C.A. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunol. Rev., 2019, Vol. 290, no. 1, pp. 127-147.

18. Chapuis A.G., Roberts I.M., Thompson J.A., Margolin K.A., Bhatia S., Lee S.M., Sloan H.L., Lai I.P., Farrar E.A., Wagener F., Shibuya K.C., Cao J., Wolchok J.D., Greenberg P.D., Yee C. T-cell therapy using interleukin21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. J. Clin. Oncol., 2016, Vol. 34, no. 31, pp. 3787-3795.

19. Cheever M.A., Greenberg P.D., Fefer A. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with interleukin 2. J. Immunol., 1981, no. 126, pp. 1318-1322.

20. Chinnasamy D., Yu Z., Kerkar S.P., Zhang L., Morgan R.A., Restifo N.P., Rosenberg S.A. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin. Cancer Res., 2012, Vol. 18, no. 6, pp. 1672-1683.

21. Chodon T., Comin-Anduix B., Chmielowski B., Koya R.C., Wu Z., Auerbach M., Ng C., Avramis E., Seja E., Villanueva A., McCannel T.A., Ishiyama A., Czernin J., Radu C.G., Wang X., Gjertson D.W., Cochran A.J., Cornetta K., Wong D.J., Kaplan-Lefko P., Hamid O., Samlowski W., Cohen P.A., Daniels G.A., Mukherji B., Yang L., Zack J.A., Kohn D.B., Heath J.R., Glaspy J.A., Witte O.N., Baltimore D., Economou J.S., Ribas A. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin. Cancer Res., 2014, Vol. 20, no. 9, pp. 2457-2465.

22. Conlon K.C., Miljkovic M.D., Waldmann T.A. Cytokines in the treatment of cancer. J. Interferon Cytokine Res., 2019, Vol. 39, no. 1, pp. 6-21.

23. Dangaj D., Bruand M., Grimm A.J., Ronet C., Barras D., Duttagupta P.A., Lanitis E., Duraiswamy J., Tanyi J.L., Benencia F., Conejo-Garcia J., Ramay H.R., Montone K.T., Powell D.J. Jr, Gimotty P.A., Facciabene A., Jackson D.G., Weber J.S., Rodig S.J., Hodi S.F., Kandalaft L.E., Irving M., Zhang L., Foukas P., Rusakiewicz S., Delorenzi M., Coukos G. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer Cell, 2019, Vol. 35, no. 6, pp. 885-900.e10.

24. Das S., Johnson D.B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer, 2019, Vol. 7, no. 1, 306. doi: 10.1186/s40425-019-0805-8.

25. de Miguel M., Umana P., Gomes de Morais A.L., Moreno V., Calvo E. T-cell-engaging Therapy for Solid Tumors. Clin. Cancer Res., 2021, Vol. 27, no. 6, pp. 1595-1603.

26. de Wolf C., van de Bovenkamp M., Hoefnagel M. Regulatory perspective on in vitro potency assays for human T cells used in anti-tumor immunotherapy. Cytotherapy, 2018, Vol. 20, pp. 601-622.

27. Diaz R.M., Galivo F., Kottke T., Wongthida P., Qiao J., Thompson J., Valdes M., Barber G., Vile R.G. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res., 2007, Vol. 67, no. 6, pp. 2840-2848.

28. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 2002, Vol. 298, no. 5594, pp. 850-854.

29. Englisch A., Altvater B., Kailayangiri S., Hartmann W., Rossig C. VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma. Pediatr. Blood Cancer., 2020, Vol. 67, no. 10, e28313. doi: 10.1002/pbc.28313.

30. Fajardo C.A., Guedan S., Rojas L.A., Moreno R., Arias-Badia M., de Sostoa J., June C.H., Alemany R. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy. Cancer Res., 2017, Vol. 77, no. 8, pp. 2052-2063.

31. Fesnak A.D., June C.H., Levine B.L. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat. Rev. Cancer, 2016, Vol. 16, no. 9, pp. 566-581.

32. Fu X., Rivera A., Tao L., Zhang X. Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery. Int. J. Cancer, 2013, Vol. 133, no. 10, pp. 2483-2492.

33. Fujiwara K., Sasawatari S., Nakai S., Imaeda K., Nagai S., Matsuno Y., Hatanaka K., Hatanaka Y., Takenaka S., Okada N. Predicting the efficacy and safety of TACTICs (tumor angiogenesis-specific CAR-T cells impacting cancers) therapy for soft tissue sarcoma patients. Cancers (Basel), 2020, Vol. 12, no. 10, 2735. doi: 10.3390/cancers12102735.

34. Garber K. Driving T-cell immunotherapy to solid tumors. Nat Biotechnol., 2018, Vol. 36, no. 3, pp. 215-219.

35. Geukes Foppen M.H., Donia M., Svane I.M., Haanen J.B. Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Mol. Oncol., 2015, no. 10, pp. 1918-1935

36. Glennie M.J., Brennand D.M., Bryden F., McBride H.M., Stirpe F., Worth A.T., Stevenson G.T. Bispecific F(ab’ gamma)2 antibody for the delivery of saporin in the treatment of lymphoma. J. Immunol., 1988, Vol. 141, no. 10, pp. 3662-3670

37. Godfrey D.I., Le Nours J., Andrews D.M., Uldrich A.P., Rossjohn J. Unconventional T cell targets for cancer immunotherapy. Immunity, 2018, Vol. 48, no. 3, pp. 453-473.

38. Goebeler M., Bargou, R.C. T cell-engaging therapies – BiTEs and beyond. Nat. Rev.Clin. Oncol., 2020, Vol. 17, pp. 418-434.

39. González-Martín A., Gómez L., Lustgarten J., Mira E., Mañes S. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res., 2011, Vol. 71, no. 16, pp. 5455-5466.

40. Granier C., de Guillebon E., Blanc C., Roussel H., Badoual C., Colin E., Saldmann A., Gey A., Oudard S., Tartour E. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open, 2017, Vol. 2, no. 2, e000213. doi: 10.1136/esmoopen-2017-000213.

41. Harlin H., Meng Y., Peterson A.C., Zha Y., Tretiakova M., Slingluff C., McKee M., Gajewski T.F. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res., 2009, Vol. 69, no. 7, pp. 3077-3085.

42. Havunen R., Siurala M., Sorsa S., Grönberg-Vähä-Koskela S., Behr M., Tähtinen S., Santos J.M., Karell P., Rusanen J., Nettelbeck D.M., Ehrhardt A., Kanerva A., Hemminki A. Oncolytic adenoviruses armed with tumor necrosis factor alpha and Interleukin-2 enable successful adoptive cell therapy. Mol. Ther. Oncolytics, 2016, Vol. 4, pp. 77-86.

43. Helguera G., Morrison S.L., Penichet M.L. Antibody-cytokine fusion proteins: harnessing the combined power of cytokines and antibodies for cancer therapy. Clin. Immunol., 2002, Vol. 105, no. 3, pp. 233-246.

44. Hu Z., Ott P.A., Wu C.J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol., 2018, Vol. 3, pp. 168-182.

45. Huang Q., Xia J., Wang L., Wang X., Ma X., Deng Q., Lu Y., Kumar M., Zhou Z., Li L., Zeng Z., Young K.H., Yi Q., Zhang M., Li Y. miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. J. Hematol. Oncol., 2018, Vol. 11, no. 1, 58. doi: 10.1186/s13045-018-0600-x.

46. Hunder N.N., Wallen H., Cao J., Hendricks D.W., Reilly J.Z., Rodmyre R., Jungbluth A., Gnjatic S., Thompson J.A., Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med., 2008, Vol. 358, no. 25, pp. 2698-2703.

47. Hutmacher C., Neri D. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy. Adv. Drug Deliv. Rev., 2019, Vol. 141, pp. 67-91.

48. Idorn M., Skadborg S.K., Kellermann L., Halldórsdóttir H.R., Holmen Olofsson G., Met Ö., Thor Straten P. Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model. Oncoimmunology, 2018, Vol. 7, no. 8, e1450715. doi: 10.1080/2162402X.2018.1450715.

49. Imai N., Ikeda H., Tawara I., Wang L., Wang L., Nishikawa H., Kato T., Shiku H. Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigenspecific CD8+ T cells with tumor regression. Cancer Sci., 2009, Vol. 100, no. 7, pp. 1317-1325.

50. Inaguma Y., Akahori Y., Murayama Y., Shiraishi K., Tsuzuki-Iba S., Endoh A., Tsujikawa J., DemachiOkamura A., Hiramatsu K., Saji H., Yamamoto Y., Yamamoto N., Nishimura Y., Takahashi T., Kuzushima K., Emi N., Akatsuka Y. Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H. Gene Ther., 2014, Vol. 21, no. 6, pp. 575-584.

51. Jin L., Tao H., Karachi A., Long Y., Hou A.Y., Na M., Dyson K.A., Grippin A.J., Deleyrolle L.P., Zhang W., Rajon D.A., Wang Q.J., Yang J.C., Kresak J.L., Sayour E.J., Rahman M., Bova F.J., Lin Z., Mitchell D.A., Huang J. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat. Commun., 2019, Vol. 10, no. 1, 4016. doi: 10.1038/s41467-019-11869-4.

52. June C.H., O’Connor R.S., Kawalekar O.U., Ghassemi S., Milone M.C. CAR T cell immunotherapy for human cancer. Science, 2018, Vol. 359, no. 6382, pp. 1361-1365.

53. Kawamura K., Tanaka Y., Nakasone H., Ishihara Y., Kako S., Kobayashi S., Tanaka Y., Ohmori T., Uchimaru K., Okamoto S., Mineno J., Shiku H., Nishimura S., Kanda Y. Development of a Unique T Cell Receptor Gene-Transferred Tax-Redirected T Cell Immunotherapy for Adult T Cell Leukemia. Biol. Blood Marrow Transplant., 2020, Vol. 8, no. 1377-1385.

54. Klebanoff C.A., Acquavella N., Yu Z., Restifo N.P. Therapeutic cancer vaccines: are we there yet? Immunol. Rev., 2011, Vol. 239, no. 1, pp. 27-44.

55. Klinger M., Brandl C., Zugmaier G., Hijazi Y., Bargou R.C., Topp M.S., Gökbuget N., Neumann S., Goebeler M., Viardot A., Stelljes M., Brüggemann M., Hoelzer D., Degenhard E., Nagorsen D., Baeuerle P.A., Wolf A., Kufer P. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood, 2012, Vol. 119, no. 26, pp. 6226-6233.

56. Kochneva G.V., Sivolobova G.F., Tkacheva A.V., Gorchakov A.A., Kulemzin S.V. Combination of oncolytic virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer. Mol. Biol. (Mosk.), 2020, Vol. 54, no. 1, pp. 3-16. (In Russ.).

57. Kulemzin S.V., Gorchakov A.A., Chikaev A.N., Kuznetsova V.V., Volkova O.Y., Matvienko D.A., Petukhov A.V., Zaritskey A.Y., Taranin A.V. VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells. Oncotarget, 2018, Vol. 9, no. 10, pp. 9021-9029.

58. Lanitis E., Kosti P., Ronet C., Cribioli E., Rota G., Spill A., Reichenbach P., Zoete V., Dangaj Laniti D., Coukos G., Irving M. VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding. J. Immunother. Cancer, 2021, Vol. 9, no. 8, e002151. doi: 10.1136/jitc-2020-002151.

59. Leko V., Rosenberg S.A. Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell, 2020, Vol. 38, no. 4, pp. 454-472.

60. Lesch S., Blumenberg V., Stoiber S., Gottschlich A., Ogonek J., Cadilha B.L, Dantes Z., Rataj F., Dorman K., Lutz J., Karches C.H., Heise C., Kurzay M., Larimer B.M., Grassmann S., Rapp M., Nottebrock A., Kruger S., Tokarew N., Metzger P., Hoerth C., Benmebarek M.R., Dhoqina D., Grünmeier R., Seifert M., Oener A., Umut Ö., Joaquina S., Vimeux L., Tran T, Hank T., Baba T., Huynh D., Megens R.T.A., Janssen K.P., Jastroch M., Lamp D., Ruehland S., di Pilato M., Pruessmann J.N., Thomas M., Marr C., Ormanns S., Reischer A., Hristov M., Tartour E., Donnadieu E., Rothenfusser S., Duewell P., König L.M., Schnurr M., Subklewe M., Liss A.S., Halama N., Reichert M., Mempel T.R., Endres S., Kobold S. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nat. Biomed. Eng., 2021, Vol. 5, no. 11, pp. 1246-1260.

61. Lev A., Noy R., Oved K., Novak H., Segal D., Walden P., Zehn D., Reiter Y. Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo. Proc. Natl Acad. Sci. USA, 2004, Vol. 101, no. 24, pp. 9051-9056.

62. Levin A.M., Bates D.L., Ring A.M., Krieg C., Lin J.T., Su L., Moraga I., Raeber M.E., Bowman G.R., Novick P., Pande V.S., Fathman C.G., Boyman O., Garcia K.C. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature, 2012, Vol. 484, no. 7395, pp. 529-533.

63. Linette G.P., Stadtmauer E.A., Maus M.V., Rapoport A.P., Levine B.L., Emery L., Litzky L., Bagg A., Carreno B.M., Cimino P.J., Binder-Scholl G.K., Smethurst D.P., Gerry A.B., Pumphrey N.J., Bennett A.D., Brewer J.E., Dukes J., Harper J., Tayton-Martin H.K., Jakobsen B.K., Hassan N.J., Kalos M., June C.H. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood, 2013, Vol. 122, no. 6, pp. 863-871.

64. Man Y.G., Stojadinovic A., Mason J., Avital I., Bilchik A., Bruecher B., Protic M., Nissan A., Izadjoo M., Zhang X., Jewett A. Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories. J. Cancer, 2013, Vol. 4, no. 1, pp. 84-95.

65. Marcuzzi E., Angioni R., Molon B., Calì B. Chemokines and chemokine receptors: orchestrating tumor metastasization. Int. J. Mol. Sci., 2018, Vol. 20, no. 1, 96. doi: 10.3390/ijms20010096.

66. Martinez M., Moon E.K. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front. Immunol., 2019, Vol. 10, 128. doi: 10.3389/fimmu.2019.00128.

67. Matko S., Teichert M., Tunger A., Schmitz M., Bornhauser M., Tonn T., Odendahl M. Enumeration of WT1-specific CD8+ T cells for clinical application using an MHC Streptamer based no-wash single-platform flowcytometric assay. Cytometry A, 2017, Vol. 91, no. 10, pp. 1001-1008.

68. Maude S.L., Frey N., Shaw P.A., Aplenc R., Barrett D.M., Bunin N.J., Chew A., Gonzalez V.E., Zheng Z., Lacey S.F., Mahnke Y.D., Melenhorst J.J., Rheingold S.R., Shen A., Teachey D.T., Levine B.L., June C.H., Porter D.L., Grupp S.A. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med., 2014, Vol. 371, no. 16, pp. 1507-1517.

69. Mikucki M.E., Fisher D.T., Matsuzaki J., Skitzki J.J., Gaulin N.B., Muhitch J.B., Ku A.W., Frelinger J.G., Odunsi K., Gajewski T.F., Luster A.D., Evans S.S. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat. Commun., 2015, Vol. 6, 7458. doi: 10.1038/ ncomms8458.

70. Mitsui J., Nishikawa H., Muraoka D., Wang L., Noguchi T., Sato E., Kondo S., Allison J.P., Sakaguchi S., Old L.J., Kato T., Shiku H. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/ inhibitory signals. Clin. Cancer Res., 2010, Vol. 16, no. 10, pp. 2781-2791.

71. Morgan R.A., Chinnasamy N., Abate-Daga D., Gros A., Robbins P.F., Zheng Z., Dudley M.E., Feldman S.A., Yang J.C., Sherry R.M., Phan G.Q., Hughes M.S., Kammula U.S., Miller A.D., Hessman C.J., Stewart A.A., Restifo N.P., Quezado M.M., Alimchandani M., Rosenberg A.Z., Nath A., Wang T., Bielekova B., Wuest S.C., Akula N., McMahon F.J., Wilde S., Mosetter B., Schendel D.J., Laurencot C.M., Rosenberg S.A. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother., 2013, Vol. 36, no. 2, pp. 133-151.

72. Nishikawa H., Kato T., Hirayama M., Orito Y., Sato E., Harada N., Gnjatic S., Old L.J., Shiku H. Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res., 2008, Vol. 68, no. 14, pp. 5948-5954.

73. Oates J., Jakobsen B.K. ImmTACs: Novel bi-specific agents for targeted cancer therapy. Oncoimmunology, 2013, Vol. 2, no. 2, e22891. doi: 10.4161/onci.22891.

74. Offner S., Hofmeister R., Romaniuk A., Kufer P., Baeuerle P.A. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol. Immunol., 2006, Vol. 43, pp. 763-771.

75. Ottolenghi A., Bolel P., Sarkar R., Greenshpan Y., Iraqi M., Ghosh S., Bhattacharya B., Taylor Z.V., Kundu K., Radinsky O., Gazit R., Stepensky D., Apte R.N., Voronov E., Porgador A. Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity. Sci. Rep., 2021, Vol. 11, no. 1, 7676. doi: 10.1038/s41598-021- 87102-4.

76. Parkhurst M.R., Yang J.C., Langan R.C., Dudley M.E., Nathan D.A., Feldman S.A., Davis J.L., Morgan R.A., Merino M.J., Sherry R.M., Hughes M.S., Kammula U.S., Phan G.Q., Lim R.M., Wank S.A., Restifo N.P., Robbins P.F., Laurencot C.M., Rosenberg S.A. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther., 2011, Vol. 19, no. 3, pp. 620-626.

77. Rafiq S., Purdon T.J., Daniyan A.F., Koneru M., Dao T., Liu C., Scheinberg D.A., Brentjens R.J. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia, 2017, Vol. 8, pp. 1788-1797.

78. Rapp M., Grassmann S., Chaloupka M., Layritz P., Kruger S., Ormanns S., Rataj F., Janssen K.P., Endres S., Anz D., Kobold S. C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer. Oncoimmunology, 2015, Vol. 5, no. 3, e1105428. doi: 10.1080/2162402X.2015.1105428.

79. Reinhard K., Rengstl B., Oehm P., Michel K., Billmeier A., Hayduk N., Klein O., Kuna K., Ouchan Y., Wöll S., Christ E., Weber D., Suchan M., Bukur T., Birtel M., Jahndel V., Mroz K., Hobohm K., Kranz L., Diken M., Kühlcke K., Türeci Ö., Sahin U. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science, 2020, Vol. 367, no. 6476, pp. 446-453.

80. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol., 2012, Vol. 12, no. 4, pp. 269-281.

81. Rohaan M.W., Wilgenhof S., Haanen J.B.A.G. Adoptive cellular therapies: the current landscape. Virchows Arch., 2019, Vol. 474, no. 4, pp. 449-461.

82. Rosenberg S.A., Mulé J.J., Spiess P.J., Reichert C.M., Schwarz S.L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med., 1985, Vol. 161, no. 5, pp. 1169-1188.

83. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., Simon P., Lotze M.T., Yang J.C., Seipp C.A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med., 1988, Vol. 319, no. 25, pp. 1676-1680.

84. Rosenberg S.A., Restifo N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 2015, Vol. 348, no. 6230, pp. 62-68.

85. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med., 2004, Vol. 9, pp. 909-915.

86. Rosenberg S.A., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., White D.E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA, 1994, Vol. 271, no. 12, pp. 907-913.

87. Rosenberg S.A. IL-2: the first effective immunotherapy for human cancer. J. Immunol., 2014, Vol. 192, no. 12, pp. 5451-5458.

88. Rosewell S.A., Suzuki M. Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment. Front. Immunol., 2018, Vol. 9, 2103. doi: 10.3389/fimmu.2018.02103.

89. Scott E.M., Duffy M.R., Freedman J.D., Fisher K.D., Seymour L.W. Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses. Macromol. Biosci., 2018, Vol. 18, no. 1. doi: 10.1002/mabi.201700187.

90. Sharma M., Khong H., Fa’ak F., Bentebibel S.E., Janssen L.M.E., Chesson B.C., Creasy C.A., Forget M.A., Kahn L.M.S, Pazdrak B., Karki B., Hailemichael Y., Singh M., Vianden C., Vennam S., Bharadwaj U., Tweardy D.J., Haymaker C., Bernatchez C., Huang S., Rajapakshe K., Coarfa C., Hurwitz M.E., Sznol M., Hwu P., Hoch U., Addepalli M., Charych D.H., Zalevsky J., Diab A., Overwijk W.W. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat. Commun., 2020, Vol. 11, no. 1, 661. doi: 10.1038/s41467-020-14471-1.

91. Siddiqui I., Erreni M., van Brakel M., Debets R., Allavena P. Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient. J. Immunother. Cancer, 2016, Vol. 4, 21. doi: 10.1186/s40425-016-0125-1.

92. Slaney C.Y., von Scheidt B., Davenport A.J., Beavis P.A., Westwood J.A., Mardiana S., Tscharke D.C., Ellis S., Prince H.M., Trapani J.A., Johnstone R.W., Smyth M.J., Teng M.W., Ali A., Yu Z., Rosenberg S.A., Restifo N.P., Neeson P., Darcy P.K., Kershaw M.H. Dual-specific chimeric antigen receptor T сells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting. Clin. Cancer Res., 2017, Vol. 23, no. 10, pp. 2478-2490.

93. Sommermeyer D., Hudecek M., Kosasih P.L., Gogishvili T., Maloney D.G., Turtle C.J., Riddell S.R. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia, 2016, Vol. 30, no. 2, pp. 492-500.

94. Spangler J.B., Moraga I., Mendoza J.L., Garcia K.C. Insights into cytokine-receptor interactions from cytokine engineering. Annu. Rev. Immunol., 2015, Vol. 33, pp. 139-167.

95. Sukari A., Abdallah N., Nagasaka M. Unleash the power of the mighty T cells-basis of adoptive cellular therapy. Crit. Rev. Oncol. Hematol., 2019, Vol. 136, pp. 1-12.

96. Tähtinen S., Grönberg-Vähä-Koskela S., Lumen D., Merisalo-Soikkeli M., Siurala M., Airaksinen A.J., VähäKoskela M., Hemminki A. Adenovirus improves the efficacy of adoptive T-cell therapy by recruiting immune cells to and promoting their activity at the tumor. Cancer Immunol. Res., 2015, Vol. 3, no. 8 , pp. 915-925.

97. Tanaka M., Tashiro H., Omer B., Lapteva N., Ando J., Ngo M., Mehta B., Dotti G., Kinchington P.R., Leen A.M, Rossig C., Rooney C.M. Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells. Clin. Cancer Res., 2017, Vol. 23, no. 14, pp. 3499-3509.

98. Tanoue K., Rosewell Shaw A., Watanabe N., Porter C., Rana B., Gottschalk S., Brenner M., Suzuki M. Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors. Cancer Res., 2017, Vol. 77, no. 8, pp. 2040-2051.

99. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 1991, Vol. 254, no. 5038 , pp. 1643-1647.

100. Vinay D.S., Ryan E.P., Pawelec G., Talib W.H., Stagg J., Elkord E., Lichtor T., Decker W.K., Whelan R.L., Kumara H.M.C.S., Signori E., Honoki K., Georgakilas A.G., Amin A., Helferich W.G., Boosani C.S., Guha G., Ciriolo M.R., Chen S., Mohammed S.I., Azmi A.S., Keith W.N., Bilsland A., Bhakta D., Halicka D., Fujii H., Aquilano K., Ashraf S.S., Nowsheen S., Yang X., Choi B.K., Kwon B.S. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin. Cancer Biol., 2015, Vol. 35 Suppl, pp. S185-S198.

101. Watanabe K., Kuramitsu S., Posey A.D. Jr, June C.H. Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology. Front. Immunol., 2018, Vol. 9, 2486. doi: 10.3389/fimmu.2018.02486.

102. Wagner J., Wickman E., Shaw T.I., Anido A.A., Langfitt D., Zhang J., Porter S.N., Pruett-Miller S.M., Tillman H., Krenciute G., Gottschalk S. Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin. Cancer Immunol. Res., 2021, Vol. 3, no. 279-290.

103. Waldmann T.A. Cytokines in Cancer Immunotherapy. Cold Spring Harb. Perspect. Biol., 2018, Vol. 10, no. 12, a028472. doi: 10.1101/cshperspect.a028472.

104. Wang W., Ma Y., Li J., Shi H.S., Wang L.Q., Guo F.C., Zhang J., Li D., Mo B.H., Wen F., Liu T., Liu Y.T., Wang Y.S., Wei Y.Q. Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. Gene Ther., 2013, Vol. 20, no. 10, pp. 970-978.

105. Wei S.C., Duffy C.R., Allison J.P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov., 2018, Vol. 9, pp. 1069-1086.

106. Wing A., Fajardo C.A., Posey A.D. Jr, Shaw C., Da T., Young R.M., Alemany R., June C.H., Guedan S. Improving CART-Cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell Engager. Cancer Immunol. Res., 2018, Vol. 5, pp. 605-616.

107. Xin G., Schauder D.M., Jing W., Jiang A., Joshi N.S., Johnson B., Cui W. Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors. Proc. Natl. Acad. Sci. USA, 2017, Vol. 114, no. 4, pp. 740-745.

108. Yeku O.O., Brentjens R.J. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem. Soc. Trans., 2016, Vol. 44, pp. 412-418.